PNC-27 Research Peptide

Introduction to PNC-27

PNC-27 is an investigational synthetic anticancer peptide designed to selectively target malignant cells through interactions with the HDM-2 (human double minute 2) protein expressed on the plasma membrane of numerous cancer cell types. Originally developed from research involving the tumor suppressor protein p53, PNC-27 incorporates a p53-derived HDM-2 binding sequence fused to a membrane transduction domain that facilitates cellular interaction.

Unlike many conventional cytotoxic agents that primarily induce apoptosis through intracellular signaling pathways, published research suggests that PNC-27 may induce rapid membrane disruption in susceptible tumor cells following binding to membrane-associated HDM-2. This proposed mechanism has generated interest in oncology research, membrane biology, tumor cell selectivity, molecular pharmacology, and targeted peptide therapeutics.

PNC-27 continues to be investigated in preclinical laboratory models and remains an important experimental tool for studying peptide-mediated cancer cell targeting.

What is PNC-27?

PNC-27 is a synthetic hybrid peptide composed of two functional domains:

* A peptide sequence derived from the HDM-2 binding region of the human p53 protein.

* A membrane penetrating peptide sequence derived from the leader sequence of the HIV-1 TAT protein.

The peptide was engineered to:

* Bind HDM-2 protein expressed on susceptible tumor cell membranes.

* Penetrate cellular membranes through the TAT-derived sequence.

* Investigate selective membrane disruption of malignant cells.

* Study peptide-based approaches to targeted oncology.

Research has evaluated PNC-27 across numerous experimental tumor models including:

* Breast carcinoma

* Pancreatic carcinoma

* Colon carcinoma

* Melanoma

* Ovarian carcinoma

* Leukemia

* Glioblastoma

* Various epithelial-derived malignancies

These investigations remain primarily preclinical.

Chemical Structure

Molecular Identity

Common Name: PNC-27

Peptide Class: Synthetic Hybrid Anticancer Peptide

Length: 32 Amino Acids

Origin: p53 HDM-2 binding domain fused to HIV-1 TAT membrane transduction sequence

Amino Acid Design

PNC-27 consists of:

* p53-derived HDM-2 binding region

* Flexible linker

* HIV TAT-derived cell-penetrating peptide

This modular design enables investigators to study both receptor recognition and membrane interaction within a single experimental peptide.

CAS Number

CAS Number: No universally recognized CAS registry number has been assigned for research-grade PNC-27.

Researchers should verify supplier-specific documentation if a proprietary synthetic preparation has been assigned an internal registry identifier.

Proposed Mechanism of Action

Current published research proposes the following sequence of events:

HDM-2 Recognition

PNC-27 binds to HDM-2 protein located on the plasma membrane of susceptible tumor cells.

Unlike the intracellular HDM-2 classically associated with p53 regulation, membrane-associated HDM-2 appears to be present in several malignant cell types investigated experimentally.

Membrane Pore Formation

Following HDM-2 binding, experimental investigations suggest PNC-27 may induce formation of transmembrane pores.

Rather than activating classical apoptotic pathways, published studies report rapid disruption of membrane integrity leading to necrotic cell death in susceptible tumor cells.

Researchers continue to investigate:

* Membrane permeability

* Pore formation

* Membrane integrity

* Cellular osmotic balance

* Cytolytic peptide mechanism

Tumor Selectivity

One of the most notable findings reported in preclinical studies is the apparent selectivity of PNC-27 toward tumor cells expressing membrane-associated HDM-2 while demonstrating minimal effects on normal cells lacking this membrane localization.

The molecular basis for this selectivity remains an active area of investigation

PNC-27 Research

Oncology Research

PNC-27 has been investigated in numerous experimental cancer models.

Published laboratory studies have reported activity against cultured cells derived from:

* Breast cancer

* Pancreatic cancer

* Colon cancer

* Melanoma

* Ovarian cancer

* Leukemia

* Glioblastoma

Researchers continue to evaluate mechanisms responsible for selective tumor targeting.

Membrane Biology

PNC-27 provides a useful model for studying:

* Plasma membrane integrity

* Peptide-induced pore formation

* Membrane protein interactions

* Cellular permeability

* Cytolytic peptide mechanisms

Understanding these processes may improve knowledge of peptide-mediated membrane disruption

HDM-2 Biology

HDM-2 remains one of the most extensively studied proteins in cancer biology.

PNC-27 has contributed to investigations involving:

* HDM-2 localization

* p53 signaling

* Tumor suppressor biology

* Protein-protein interactions

* Membrane-associated HDM-2

These studies continue to expand understanding of HDM-2 biology beyond its traditional intracellular role.

Cellular Death Mechanisms

Experimental investigations have examined whether PNC-27 induces:

* Necrosis

* Membrane lysis

* Osmotic cell death

* Apoptosis-independent cytotoxicity

* Rapid membrane disruption

These mechanisms distinguish PNC-27 from many conventional chemotherapeutic agents that primarily activate programmed cell death pathways.

Molecular Pharmacology

Researchers continue investigating:

* Peptide stability

* Structure-activity relationships

* HDM-2 binding affinity

* Cellular uptake

* Membrane interaction kinetics

These studies may assist future development of targeted peptide therapeutics.

Potential In Vitro Research Applications

Research-grade PNC-27 may be utilized in investigations involving:

* Cancer cell culture

* HDM-2 expression studies

* Tumor membrane biology

* Cytotoxicity assays

* Membrane permeability assays

* Cell viability assays

* Flow cytometry

* Confocal microscopy

* Structure-activity relationship studies

* Peptide engineering

* Molecular oncology

* Drug discover

Future Research Directions

Current investigations continue to explore:

Precision Oncology

Determining which tumor types demonstrate membrane-associated HDM-2 expression and identifying biomarkers that predict responsiveness.

Structure-Activity Relationships

Engineering modified PNC-27 analogs with improved stability, selectivity, receptor affinity, or pharmacokinetic properties.

Combination Research

Evaluating PNC-27 alongside chemotherapy, targeted agents, radiation, immunotherapy, and other investigational peptide therapeutics in preclinical models.

Drug Delivery

Investigating nanoparticle formulations, liposomal encapsulation, hydrogel delivery systems, and targeted peptide delivery platforms.

Membrane Biology

Further defining the molecular mechanism of pore formation and membrane disruption.

Translational Oncology

Additional preclinical research is required before the potential clinical relevance of PNC-27 can be determined.

Product Specifications

Product Name: PNC-27

Peptide Class: Synthetic Hybrid Anticancer Research Peptide

Length: 32 Amino Acids

Target: HDM-2

CAS Number: No universally assigned CAS registry number

Research Classification: Experimental Oncology Research Peptide

Intended Use: In vitro laboratory research only

Scientific Summary

PNC-27 is an investigational synthetic peptide engineered from the HDM-2 binding domain of p53 and a membrane transduction sequence derived from HIV-1 TAT. Published preclinical studies suggest that PNC-27 selectively targets tumor cells expressing membrane-associated HDM-2 and may induce rapid membrane disruption through pore formation. These unique properties have established PNC-27 as an important research tool for investigating peptide-mediated tumor targeting, membrane biology, molecular oncology, and next-generation peptide therapeutics.

References

1. , et al. PNC-27, a p53-derived membrane-active peptide, induces cancer cell membrane pore formation. Proceedings of the National Academy of Sciences (PNAS).

https://www.pnas.org

2. , et al. Selective cytotoxicity of PNC-27 against cancer cells expressing membrane HDM-2.

https://pubmed.ncbi.nlm.nih.gov

3. . Reviews on p53 and HDM-2 biology.

https://pubmed.ncbi.nlm.nih.gov

4. National Center for Biotechnology Information.

https://pubmed.ncbi.nlm.nih.gov/?term=PNC-27

5. National Center for Biotechnology Information.

https://pmc.ncbi.nlm.nih.gov/?term=PNC-27

Disclaimer

This information is provided solely for research and educational purposes. PNC-27 is not approved by the United States Food and Drug Administration (FDA) or any other regulatory authority for human or veterinary use. PNC-27 is intended exclusively for in vitro studies, laboratory research, analytical testing, and experimental applications conducted by qualified researchers.

PNC-27 is not intended for human consumption, clinical use, therapeutic use, veterinary use, diagnostic use, or administration to humans or animals. Researchers are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional guidelines governing the purchase, handling, storage, and use of research materials.